About RestoreFlow Allografts
RestoreFlow Allografts is a company based in Fox River Grove (United States) founded in 2013 was acquired by LeMaitre Vascular in November 2016. RestoreFlow Allografts has raised $750 thousand across 1 funding round from investors including LeMaitre Vascular. RestoreFlow Allografts operates in a competitive market with competitors including MiMedx Group, Satellite Bio, KaloCyte, Stratatech Corp and CorNeat Vision, among others.
- Headquarter Fox River Grove, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$750 K (USD)
in 1 rounds
-
Latest Funding Round
$750 K (USD), Seed
Jun 13, 2013
- Investors
-
Employee Count
Not available
-
Acquired by
LeMaitre Vascular
(Nov 10, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of RestoreFlow Allografts
RestoreFlow Allografts has successfully raised a total of $750K through 1 strategic funding round. The most recent funding activity was a Seed round of $750 thousand completed in June 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in RestoreFlow Allografts
RestoreFlow Allografts has secured backing from 1 investor. Prominent investors backing the company include LeMaitre Vascular.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Devices for peripheral vascular disease treatment are developed and marketed.
|
Locked | Locked | Locked |
Investor details for RestoreFlow Allografts
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RestoreFlow Allografts
Investment portfolio details for RestoreFlow Allografts
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RestoreFlow Allografts
Detailed financials for RestoreFlow Allografts
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Restoreflow Allografts Comparisons
Peer comparison for RestoreFlow Allografts
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RestoreFlow Allografts
RestoreFlow Allografts operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MiMedx Group, Satellite Bio, KaloCyte, Stratatech Corp and CorNeat Vision, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Regenerative biomaterial products and bioimplants for wound, surgical, sports medicine and orthopedics
|
|
| Locked | Locked | Locked |
Proprietary implantable satellite organs are developed for cell therapy.
|
|
| Locked | Locked | Locked |
Nanotechnology-based red blood cell substitutes are developed.
|
|
| Locked | Locked | Locked |
Cell-based skin substitutes are developed for therapeutic and research uses.
|
|
| Locked | Locked | Locked |
Nanotechnology-based artificial corneal implants are developed for ophthalmic use.
|
|
| Locked | Locked | Locked |
Developer of surgical mesh for wound management
|
Detailed competitors of RestoreFlow Allografts
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Restoreflow Allografts
Complete news archive for RestoreFlow Allografts
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RestoreFlow Allografts
RestoreFlow Allografts was founded in 2013.
RestoreFlow Allografts is headquartered in Fox River Grove, United States. It is registered at Fox River Grove, Illinois, United States.
Torico D Jones is the current CEO of RestoreFlow Allografts.
RestoreFlow Allografts is a funded company, having raised a total of $750K across 1 funding round to date.
RestoreFlow Allografts was established in 2013 in Fox River Grove, United States. Human tissue-based regenerative medicines are developed by the company to treat various diseases within the biotechnology sector. Operations center on research and production of these therapies. Leadership is held by CEO Torico D Jones, with activities conducted primarily in the U.S. market.
RestoreFlow Allografts's top competitors include MiMedx Group, KaloCyte and Satellite Bio.
RestoreFlow Allografts has 1 investor. Key investors include LeMaitre Vascular.